C. Hézode

8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

C. Hézode, Céline Dorival, Fabien Zoulim et al. · Journal of Hepatology · 2012 · 88 citations

Anrs Co20-cupic, Patient Safety, Antiviral Drug Development +4

1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS

Gregory T. Everson, Karen Sims, M. Rodríguez‐Torres et al. · Journal of Hepatology · 2013 · 37 citations · Full text

Hepatology, Hepatitis C, Regimen Of Daclatasvir +11

60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

H. Fontaine, C. Hézode, Céline Dorival et al. · Journal of Hepatology · 2013 · 37 citations

Anrs Co20-cupic, Treatment And Prevention, Immunodeficiencies +4

68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C

C. Hézode, Françoise Roudot‐Thoraval, Pascale Grenard et al. · Journal of Hepatology · 2004 · 33 citations

Cannabis Use, Tobacco Control, Hepatology +8

1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT

Stefan Zeuzem, Graham R. Foster, Michael Fried et al. · Journal of Hepatology · 2011 · 29 citations · Full text

Viral Persistence, Viral Hepatitis, Immunodeficiencies +7